AZNAcerta Pharma BVRunning, no new patients
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
Chronic Lymphocytic Leukemia
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 310 (final count)
- Started
- Feb 2, 2017
- Main results expected
- Sep 3, 2021
- Fully finished
- Oct 1, 2027
- Results posted
- Jun 29, 2023
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free Survival (PFS) Per Independent Review Committee (IRC) Assessment
Measured over: IRC assessments from randomization date until disease progression or death or IRC discontinuation on 15Jan2019 (as IA per this data cutoff showed crossing superiority boundary) whichever came first, up to 22 months of follow-up
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT02970318 · record last updated 2026-10-23 · checked 2026-11-09 15:47 UTC